Jasper Therapeutics, Inc. Logo

Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):
US4718712023 (+3 more)
LEI:
Country:
United States of America
Address:
2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America
SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America
SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America
SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea
298060
scPharmaceuticals Inc. Logo
Commercializes subcutaneous drug-device therapies for at-home cardiorenal care.
United States of America
SCPH
SCYNEXIS INC Logo
Developing novel anti-fungal therapies for difficult-to-treat, drug-resistant infections.
United States of America
SCYX
Seach Medical Group Ltd. Logo
Researches, cultivates, and produces certified medical cannabis oils and flowers for global markets.
Israel
SEMG
SEEGENE, INC. Logo
Develops multiplex qPCR diagnostic assays and automated systems for labs and healthcare worldwide.
South Korea
096530
SEIKAGAKU CORPORATION Logo
A research pharma company using glycoscience to develop drugs for orthopedic & ophthalmic diseases.
Japan
4548
SELLAS Life Sciences Group, Inc. Logo
Late-stage biopharma developing novel immunotherapies for a broad range of cancers.
United States of America
SLS

Talk to a Data Expert

Have a question? We'll get back to you promptly.